-
What Did My Patient Actually Take? An Overview of Marijuana (THC) Results
Marijuana Overview The interpretation of marijuana results differs when considering presumptive vs. definitive testing methods, and may also differ among…
-
Unpredictability of Counterfeit Drugs
Novel Psychoactive Substances (NPS) are developed to bypass controlled drug legislation and evade detection by traditional drug testing methods. In many…
-
Novel Psychoactive Testing in Oral Fluid
Novel Psychoactive Substances Added to Oral Fluid Testing Menu Aegis’ oral fluid testing menu has been expanded to allow providers the option to test…
-
Opioid Drug Interactions: Ongoing Awareness Amidst the COVID-19 Pandemic and Opioid Epidemic
In recent years, there has been a significant growth in the understanding of prescription opioid use and misuse, addiction, and overdose. This has led…
-
Staying Safe: The Importance of Medication Monitoring as the Pandemic Continues
The COVID-19 pandemic continues to pose significant challenges to the healthcare system, despite widespread availability of vaccines. Variants of the virus…
-
Cases of Unusual Buprenorphine Concentrations in Urine Drug Tests: What Does This Mean and Clinical Implications?
Buprenorphine is a semisynthetic opioid with partial agonist activity at the mu-opioid receptor, an effective treatment option for opioid use disorder…
-
NPS Focus: “Nitazene" Synthetic Opioids
Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive Substances (NPS) in mid-2020, which includes phenibut, tianeptine,…